Effect of nomegestrol acetate on estronesulfatase and 17ß-hydroxysteroid dehydrogenase activities in human breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 58, Issue 5-6, 1996, Pages 525-531

  Chetrite, G ^a   Paris, J ^b   Botella, J ^b   Pasqualini, J R ^a  

^a Hormones and Cancer Research Unit   (France)

^b MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MINK CELL FOCUS-FORMING VIRUS;

3(17) HYDROXYSTEROID DEHYDROGENASE; 3(17)-HYDROXYSTEROID DEHYDROGENASE; ESTRONE SULFATASE; HYDROXYSTEROID DEHYDROGENASE; MEGESTROL; NOMEGESTROL ACETATE; PREGNANE DERIVATIVE; SULFATASE;

ARTICLE; BREAST TUMOR; CELL CULTURE; ENZYMOLOGY; FEMALE; HUMAN; PATHOLOGY;

BREAST NEOPLASMS; FEMALE; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MEGESTROL; NORPREGNADIENES; SULFATASES; TUMOR CELLS, CULTURED;

EID: 0030203952     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-0760(96)00094-5     Document Type: Article

References (47)

1. Henderson J. C. and Cannellos G. P.: Cancer of the breast: the last decade. New Engl. J. Med. 302 (1980) 17-30.
2. Stoll B. A.: Perspectives on hormonal therapy in cancer. In Clinics in Oncology (Edited by Furr B. J. A.). W.B. Saunders, New York, Vol. I (1982) pp. 3-19.
3. Dao T. L., Hayes C. and Libby P. R.: Steroid sulfatase activities in human breast tumors. Proc. Soc. Exp. Biol. Med. 146 (1974) 381-384.
4. Pasqualini J. R., Schatz B., Varin C. and Nguyen B.-L.: Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J. Steroid Biochem. Molec. Biol. 41 (1992) 323-329.
5. Perel E., Wilkins D. and Killinger D. W.: The conversion of androstenedione to estrone, estradiol, and testosterone in breast tissue. J. Steroid Biochem. 13 (1980) 89-94.
6. Silva M. C., Rowlands M. G., Dowsett M., Gusterson B., McKinna J. A., Fryatt I. and Coombes R. C.: Intratumoral aromatase as a prognostifator in human breast carcinoma. Cancer Res. 49 (1989) 2588-2591.
7. Abul-Hajj Y. J.: Relationship between estrogen receptors, 17ß-hydroxysteroid dehydrogenase and estrogen content in human breast cancer. Steroids 34 (1979) 217-225.
8. Vermeulen A., Deslypere J. P., Paridaens R., Leclercq G., Roy F. and Heuson J. C.: Aromatase, 17ß-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur. J. Cancer Clin. Oncol. 22 (1986) 515-525.
9. Santner S. J., Feil P. D. and Santen R. J.: In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocr. Metab. 59 (1984) 29-33.
10. Pasqualini J. R., Chetrite G., Nguyen B.-L., Blacker C., Feinstein M.-C., Maloche C., Talbi M. and Delalonde L.: Control of estrone sulfatase activity and its expression in human breast cancer. In Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects (Edited by Motta M. and Serio M.). Excerpta Medica Int. Congr. Ser., Vol. 1064. Elsevier Science BV, Amsterdam (1994) pp. 257-265.
11. Pasqualini J. R., Chetrite G., Blacker C., Feinstein M.-C., Delalonde L., Talbi M. and Maloche C.: Concentration of estrone, estradiol, estrone sulfate, and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocr. Metab. 81 (1996) 1460-1464.
12. Pasqualini J. R. and Gelly C.: Biological response of the antiestrogen ICI 164,384 in human hormone-dependent and hormone-independent mammary cancer cell lines. Cancer Lett. 50 (1990) 133-139.
13. Pasqualini J. R. and Nguyen B.-L.: Estrone sulfatase activity and effect of antiestrogens on transformation of estrone sulfate in hormone-dependent vs. -independent human breast cancer cell lines. Breast Cancer Res. Treat. 18 (1991) 93-98.
14. Pasqualini J. R., Varin C. and Nguyen B.-L.: Effect of the progestagen R5020 (Promegestone) and of progesterone on the uptake and on the transformation of estrone sulfate in the MCF-7 and T-47D human mammary cancer cells Correlation with progesterone receptor levels. Cancer Lett. 66 (1992) 55-60.
15. Nguyen B.-L., Fermé I., Chetrite G. and Pasqualini J. R.: Action of Danazol on the conversion of estrone sulfate to estradiol and on the sulfatase activity in the MCF-7, T-47D and MDA-MB-231 human mammary cancer cells. J. Steroid Biochem. Molec. Biol. 46 (1993) 17-23.
16. Fraser D. I., Padwick M. L., Whitehead M. I., White J., Ryder T. A. and Pryse D. J.: The effects of the addition of nomegestrol acetate to postmenopausal oestrogen therapy. Maturitas 11 (1989) 21-34.
17. Basdevant A., Pelissier C., Conard J., Degrelle H., Guyene T. T. and Thomas J. L.: Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception 44 (1991) 599-605.
18. Coutinho E. M.: One year contraception with a single subdermal implant containing nomegestrol acetate. Contraception 47 (1993) 97-105.
19. Botella J., Duranti E., Duc I., Cognet A. M., Delansorne R. and Paris J.: Inhibition by nomegestrol acetate and other synthetic progestins on proliferation and progesterone receptor content of T-47D human breast cancer cells. J. Steroid Biochem. Molec. Biol. 50 (1994) 41-47.
20. Botella J., Duc I., Delansorne R., Paris J. and Lahlou B.: Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J. Pharm. Exp. Ther. 248 (1989) 758-761.
21. Botella J., Duranti E., Viader V., Duc I., Delansorne R. and Paris J.: Lack of estrogenic potential of progesterone- or 19-nor-progesterone-derived progestins as opposed to testosterone or 19-nor-testosterone derivatives on endometrial Ishikawa cells. J. Steroid Biochem. Molec. Biol. 55 (1995) 77-84.
22. Catherino W. H. and Jordan V. C.: Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity. J. Steroid Biochem. Molec. Biol. 55 (1995) 239-246.
23. Burton K.: A study of the conditions and mechanism of the diphenylamine reaction for the calorimetric estimation of deoxyribonucleic acid. Biochem. J. 62 (1956) 315-323.
24. MacIndoe J. H.: The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology 123 (1988) 1281-1287.
25. Bearden J.C. Jr.: Quantitation of submicrogram quantities of protein by an improved protein-dye binding assay. Biochim. Biophys. Acta 533 (1978) 525-531.
26. Nguyen B. L., Chetrite G. and Pasqualini J. R.: Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Breast Cancer Res. Treat. 34 (1995) 139-146.
27. Ansfield F. J., Davis H. L., Ellerby R. A. and Ramirez G.: A clinical trial of megestrol acetate in advanced breast cancer. Cancer 3 (1984) 907-910.
28. Santen R. J., Manni A., Harvey H. and Redmond C.: Endocrine treatment of breast cancer in women. Endocr. Rev. 11 (1990) 221-265.
29. Malet C., Vacca A., Kuttenn F. and Mauvais-Jarvis P.: 17ß-Estradiol dehydrogenase (E2DH) activity in T47D cells. J. Steroid Biochem. Molec. Biol. 39 (1991) 769-775.
30. Prudhomme J. F., Malet C., Gompel A., Lalardrie J. P., Ochoa C., Boué A., Mauvais-Jarvis P. and Kuttenn F.: 17ß-hydroxysteroid dehydrogenase activity in human breast epithelial cell and fibroblast cultures. Endocrinology 114 (1984) 1483-1489.
31. Gompel A., Malet C., Spritzer P., Lalardrie J. P., Kuttenn F. and Mauvais-Jarvis P.: Progestin effect on cell proliferation and 17ß-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J. Clin. Endocr. Metab. 63 (1986) 1174-1180.
32. Fournier S., Kuttenn F., De Cicco N., Baudot N., Malet C. and Mauvais-Jarvis P.: Estradiol 17ß-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J. Clin. Endocr. Metab. 55 (1982) 428-433.
33. Singh A. and Reed M. J.: Insulin-like growth factor type I and Insulin-like growth factor type II stimulate oestradiol-17ß-hydroxysteroid dehydrogenase (reductive) activity in breast cancer cells. J. Molec. Endocr. 129 (1991) R5-R8.
34. Adams E. F., Newton C. J., Tait G. H., Braunsberg H., Reed M. J. and James V. H. T.: Paracrine influence of human breast stromal fibroblasts on breast epithelial cells; secretion of a polypeptide which stimulate reductive 17ß-oestradiol dehydrogenase activity. Int. J. Cancer 42 (1988) 119-122.
35. Chetrite G., Varin C., Delalonde L. and Pasqualini J. R.: Effect of promegestone, tamoxifen, 4-hydroxytamoxifen and ICI 164,384 on the oestrone sulphatase activity of human breast cancer cells. Anticancer Res. 13 (1993) 931-934.
36. Pasqualini J. R., Maloche C., Maroni M. and Chetrite G.: Effect of the progestagen (R-5020) on mRNA of the oestrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Res. 14 (1994) 1589-1594.
37. Prost-Avallet O., Oursin J. and Adessi G.: In vitro effect of synthetic progestogens on estrone sulfatase activity in human breast carcinoma. J. Steroid Biochem. Molec. Biol. 39 (1991) 967-973.
38. Poutanen M., Montcharmont B. and Vihko R.: 17ß-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res. 52 (1992) 290-294.
39. Botella J., Paris J. and Lahlou B.: The cellular mechanism of the antiandrogenic action of nomegestrol acetate, a new 19-norprogesterone on the rat prostate. Acta Endocrinol. 115 (1987) 544-550.
40. Duc I., Botella J., Bonnet P., Fraboul F., Delansorne R. and Paris J.: Antiandrogenic properties of nomegestrol acetate. Arzneim. - Forsch./Drug Res. 45 (1995) 70-74.
41. Botella J., Duc I., Delansorne R., Paris J. and Lahlou B.: Structure-activity and structure-affinity relationships of 19-norprogesterone derivatives in rat uterus. J. Endocr. Invest. 13 (1990) 905-910.
42. Botella J., Porthe-Nibelle J., Paris J. and Lahlou B.: Interaction of new 19-nor-progesterone derivatives with progestagen, mineralocorticoid and glucocorticoid cytosolic receptors. J. Pharmacol. 17 (1986) 699-706.
43. Keydar I., Chen L., Karby S., Weiss F. R., Delarea J., Radu M., Chaitcik S. and Brenner H. J.: Establishment and characterization of cell line of human breast-carcinoma origin. Eur. J. Cancer 15 (1979) 659-760.
44. Horwitz K. B., Zava D. T., Thilagar A. K., Jensen E. M. and McGuire W. L.: Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res. 38 (1978) 2434-2437.
45. Clarke C. L. and Sutherland R. L.: Progestin regulation of cellular proliferation. Endocr. Rev. 11 (1990) 266-301.
46. Musgrove E. A., Lee C. S. L. and Sutherland R. L.: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos and c-myc genes. Molec. Cell. Biol. 11 (1991) 5032-5043.
47. Kalkhoven E., Kwakkenbos-Isbrücker L., Mummery C. L., De Laat S. W., Van den Eijnden-van Raaij A. J. M., Van der Saag P. T. and Van der Burg B.: The role of TGF-ß production in growth inhibition of breast-tumor cells by progestins. Int. J. Cancer 61 (1995) 80-86.